3-Acetamino-benzolsulfonsaeuredimethylamid | 22184-91-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-Acetamino-benzolsulfonsaeuredimethylamid
• 英文别名: N-Acetyl-3-dimethylaminosulfonyl-anilin；N-(3-Dimethylsulfamoyl-phenyl)-acetamide；N-[3-(dimethylsulfamoyl)phenyl]acetamide
• CAS: 22184-91-4
• 化学式: C₁₀H₁₄N₂O₃S
• mdl: MFCD02575462
• 分子量: 242.299
• InChiKey: XAJGFMCFZVWWPH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  74.9
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• BENZENESULFONAMIDE UPREGULATORS OF NPC1 FOR NEIMANN-PICK DISEASE AND OTHER LYSOSOMAL STORAGE DISORDERS
  申请人：ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI

  公开号：US20180044286A1

  公开（公告）日：2018-02-15

  Methods and compositions for treating lysosomal storage disorders are disclosed. The methods involve administering a genus of benzenesulfonamides, particularly N-[3-(aminosulfonyl)phenyl]-benzamides and heteroarylamides. A genus of suitable compounds is shown in formula 1:

  本发明公开了治疗溶酶体贮积病的方法和组合物。该方法涉及使用苯磺酰胺属的一类化合物，特别是N-[3-(氨基磺酰基)苯基]-苯甲酰胺和杂环苯甲酰胺。适用化合物属于公式1所示的一类化合物。
• Benzenesulfonamide upregulators of NPC1 for Neimann-Pick disease and other lysosomal storage disorders
  申请人：ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI

  公开号：US10239830B2

  公开（公告）日：2019-03-26

  Methods and compositions for treating lysosomal storage disorders are disclosed. The methods involve administering a genus of benzenesulfonamides, particularly N-[3-(aminosulfonyl)phenyl]-benzamides and heteroarylamides. A genus of suitable compounds is shown in formula 1:

  本发明公开了治疗溶酶体贮积症的方法和组合物。这些方法包括施用苯磺酰胺类化合物，特别是 N-[3-（氨基磺酰基）苯基]-苯酰胺和杂芳基酰胺。合适的化合物属如式 1 所示：
• COMPOUNDS FOR USE IN STABILIZING P53 MUTANTS
  申请人：Boeckler Frank

  公开号：US20110059953A1

  公开（公告）日：2011-03-10

  Compounds of formula (I): wherein X is selected from CR X and N; R N1 is selected from H and C 1-4 alkyl, which may be substituted by SH or halo; R G1 is selected from H and SH; R C2 is selected from H and optionally substituted C 1-7 alkyl; R C3 is selected from H and optionally substituted C 1-7 alkyl; R x is selected from H, OH and NH 2 ; R C4 is selected from: (i) an optionally substituted C 3-12 N-containing heterocyclyl; (ii) C(═O)NR N5 R N6 , where R N5 and R N6 are independently selected from H, optionally substituted C 1-7 alkyl, optionally substituted C 3-20 heterocyclyl and optionally substituted C 5-20 aryl or RN5 and RN6 and the nitrogen atom to which they are attached form an optionally substituted N-containing C 5-7 heterocyclyl group; (iii) C(═O)OR O1 , where R O1 is selected from H, optionally substituted C 1-7 alkyl, optionally substituted C 3-20 heterocyclyl and optionally substituted C 5-20 aryl; (iv) C(═O)NHNHSO 2 R S1 , where R S1 is selected from H, optionally substituted C 1-7 alkyl, optionally substituted C 3-20 heterocyclyl and optionally substituted C 5-20 aryl; (v) OC(═O)RC8, where RC8 is selected from H, optionally substituted C 1-7 alkyl, optionally substituted C 3-20 heterocyclyl and optionally substituted C 5-20 aryl; (vi) OC(═O)NR N7 R N8 , where R N7 and R N8 are independently selected from H, optionally substituted C 1-7 alkyl, optionally substituted C 3-20 heterocyclyl and optionally substituted C 5-20 aryl or R N7 and R N8 and the nitrogen atom to which they are attached form an optionally substituted N-containing C 5-7 heterocyclyl group; and (vii) C(═O)CH 2 NH C(═O)NHNH 2 , CHC(CN) 2 , CHC(CN)C(═O)NH 2 , and carboxy; R C5 is selected from H, OH and NH 2 ; or R C4 and R C5 together with the carbon atoms to which they are bound form an optionally substituted aromatic ring containing either 5 or 6 ring atoms, of formula: where Q represents O, N, or CR Q1 ═CR Q2 , where R Q1 and R Q2 are independently selected from H, OH and NH 2 ; R C6 is selected from H, OH and NH 2 ; and R C7 is selected from optionally substituted C3_12 N-containing heterocyclyl, NHC(═O)R C9 , CH 2 NR N2 R N3 and NHC(═S)NHR N4 , where R C9 is selected from optionally substituted C 1-7 alkyl, optionally substituted C 3-20 heterocyclyl and optionally substituted C 5-20 aryl, R N2 and R N3 are independently selected from H, optionally substituted C 1-7 alkyl, optionally substituted C 3-20 heterocyclyl and optionally substituted C 5-20 aryl or R N2 and R N3 and the nitrogen atom to which they are attached form an optionally substituted N-containing C 5-7 heterocyclyl group, and R N4 is selected from optionally substituted C 1-7 alkyl, optionally substituted C 3-20 heterocyclyl and optionally substituted C 5-20 aryl, and when R C4 and R C5 are not bound together, R C3 may additionally be selected from OR 02 , where R O2 is a C 1-4 alkyl group, and C(═O)OR O3 , where R O3 is a C 1-4 alkyl group and R C2 may additionally be selected from halo, for use in stabilising a p53 protein carrying a Y220C mutation.